"All of us at FUJIFILM Biosciences take immense pride in being a people-focused company that empowers our colleagues to create an exceptional customer experience,†said Brandon Pence, president and chief operating officer, FUJIFILM Biosciences. "We utilize our 55-year legacy of deep industry knowledge to collaboratively develop innovative solutions and technologies that are supplied from our global network of manufacturing facilities. With this approach and our ongoing investments, we look ahead to a stron ...

Core Insights - Thermo Fisher Scientific reported Q2 2025 results with revenue of $10.85 billion and adjusted EPS of $5.36, exceeding Wall Street estimates [1][2] - The company faced declining profit margins despite strong revenue growth and product launches [1][5] Financial Performance - Revenue (GAAP) increased by 2.9% year-over-year from $10.54 billion in Q2 2024 to $10.85 billion in Q2 2025 [2] - Non-GAAP EPS was $5.36, slightly down by 0.2% from $5.37 in Q2 2024 [2] - Free cash flow (non-GAAP) fell by 33.5% to $1.11 billion compared to $1.67 billion in Q2 2024 [2][8] - Operating margin (GAAP) decreased by 0.4 percentage points to 16.9% [2][8] Segment Performance - Life Sciences Solutions revenue grew by 5.9% to $2.50 billion, benefiting from pharmaceutical R&D and manufacturing demand [2][5] - Analytical Instruments segment saw a 3.0% decline in revenue year-over-year, with operating margin dropping by 5.8 percentage points to 18.8% [2][6] Innovation and R&D - The company launched several next-generation scientific instruments, including the Orbitrap Astral Zoom mass spectrometer and Krios 5 Cryo-TEM [7] - R&D spending increased to $352 million, representing 3.2% of revenue, indicating a commitment to innovation [7] Strategic Moves - The company acquired Sanofi's sterile fill-finish facility to expand U.S. manufacturing capabilities [9] - A pending acquisition of Solventum filtration is expected to close by year-end, aimed at building future capacity [9] Market Diversification - Thermo Fisher's revenue base is diversified across biopharmaceutical, diagnostic, academic, and government sectors, helping to mitigate risks from slowdowns in specific areas [10] Financial Outlook - The company projects FY2025 revenue between $43.3 billion and $44.2 billion, with adjusted EPS expected in the range of $21.76 to $22.84 [11] - Management anticipates completing supply chain actions to offset tariff-related cost pressures by 2026 [11]